Benjamin Adam Weinberg, MD, Georgetown University, Washington, DC, provides an overview of innovative strategies in the treatment of pancreatic cancer. Despite the introduction of liposomal irinotecan and recent findings from the Phase III NAPOLI-3 trial (NCT04083235), survival rates have not drastically improved over the past decade. Dr Weinberg additionally highlights the need to find new targets and actionable subtypes of pancreatic cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.